Shikha Kaushik

Shikha Kaushik

Auto-generated profile, based on publicly available information

Shikha Kaushik

KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, Uttar Pradesh, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
PBPankaj Bhatt
Pankaj Bhatt
VKVipin Kumar
Vipin Kumar
RGRicha Goel
Richa Goel
SSSomesh Kumar Sharma
Somesh Kumar Sharma
SKShikha Kaushik
Shikha Kaushik
MTMulugeta Tesema
Mulugeta Tesema
Pharmaceutical excipients are compounds or substances other than API which are added to a dosage form, these excipients basically act as carriers, binders, bulk forming agents, colorants, and flavouring agents, and few excipients are even used to enhance the activity of active pharmaceutical ingredient (API) and various more properties. However, despite of these properties, there are problems with the synthetic excipients such as the possibility of causing toxicity, inflammation, autoimmune responses, lack of intrinsic bioactivity and biocompatibility, expensive procedures for synthesis, and water solubility. However, starch as an excipient can overcome all these problems in one go. It is inexpensive, there is no toxicity or immune response, and it is biocompatible in nature. It is very less used as an excipient because of its high digestibility and swelling index, high glycemic index, paste clarity, film‐forming property, crystalline properties, etc. All these properties of starch can be altered by a few modification processes such as physical modification, genetic modification, and chemical modification, which can be used to reduce its digestibility and glycemic index of starch, improve its film‐forming properties, and increase its paste clarity. Changes in some of the molecular bonds which improve its properties such as binding, crystalline structure, and retrogradation make starch perfect to be used as a pharmaceutical excipient. This research work provides the structural modifications of native starch which can be applicable in advanced drug delivery. The major contributions of the paper are advances in the modification of native starch molecules such as physically, chemically, enzymatically, and genetically traditional crop modification to yield a novel molecule with significant potential for use in the pharmaceutical industry for targeted drug delivery systems.

30 December 2024 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
RGRoma Ghai
Roma Ghai
AMAshu Mittal
Ashu Mittal
DPDeepali Pandey
Deepali Pandey
SAShamshir Alam
Shamshir Alam
SKShikha Kaushik
Shikha Kaushik
SMShardendu Kumar Mishra
Shardendu Kumar Mishra
Drug administration at similar doses in patients can often lead to various clinical responses. It has been hypothesized that genetics primarily accounts for variation in drug efficacy and toxicity in individuals. Personalized medicine has been a breakthrough achieved by the Human Genome Project which contributes to enhancing quality-based patient care. It deals with the customization of medication considering the distinct genetic and proteomic data that underpins the originality of every patient and every instance of therapeutic intervention. Many cases have shown that inter-individual differences related to drug response can be traced to genetic polymorphism in the gene alleles that codes for metabolizing enzymes, drug transporters, and genetic variations in a person’s Major Histocompatibility Complex (MHC). So, the paper throws an insight into epidemiological variations due to genetics, variations in response based on metabolic parameters, and transporters. It also covers genetic variation related to immune-related drug toxicities. Pharmacogenetic testing plays an important role in achieving more precise personalized therapeutics for better public health. The paper discusses various tests for human leukocyte antigen variants and metabolic variants. Every technology inclusion comes with advantages and limitations so personalized medicine also faces certain challenges which are discussed in the paper. Once personalized medicine is used in clinical settings, patients will be able to receive the best medications for them based on their unique genetic and protein profiles.

1 June 2026 in Letters in Drug Design & Discovery
Verified
Journal Article
Open access
SKShikha Kaushik
Shikha Kaushik
VPVaishali M. Patil
Vaishali M. Patil
PSPragya Sharma
Pragya Sharma
SBShivangi Bharadwaj
Shivangi Bharadwaj
PDPriyanka Dubey
Priyanka Dubey
SPSarvesh Kumar Paliwal
Sarvesh Kumar Paliwal